Sakhamuri Sivakesava reported grant involving 90,000 derivative units of CRISPR Therapeutics AG at $0.00 for $0 on Nov 4, 2026

Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
Chief Technical Officer
Chief Technical Officer
Filed Nov 6, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
$0Shares × reported price
Shares traded
90,000Stock Option (Right to Buy)
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
90,000Direct
Trade date
Nov 4, 2026Grant
Filed
Nov 6, 2026, 5:35 PM ET2-day reporting delay
Accession
0001193125-26-452143Code A · Transaction 395246
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Nov 4, 2026Grant40,000$0.00$0Trade 395247
2 transaction rows in this filing. Joint filers share the same rows.

CRSP price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
CRSP · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +15%1w ago +8.1%1d ago −0.2%
Returns since7d −16%30d90d180d1y

Footnotes in full

F1: This option was granted on November 4, 2026 with respect to 90,000 Common Shares. 25% of the shares shall vest on November 2, 2027, and the remaining shares shall vest in 36 equal monthly installments thereafter. F2: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F3: This restricted stock unit award was granted on November 4, 2026 with respect to 40,000 Common Shares, with (i) one quarter of the shares vesting on November 2, 2027, (ii) one quarter of the shares vesting on November 2, 2028, (iii) one quarter of the shares vesting on November 2, 2029, and (iv) one quarter of the shares vesting on November 2, 2030.